Scotia Capital Inc. Has $750,000 Stock Holdings in Haleon plc (NYSE:HLN)

Scotia Capital Inc. raised its stake in Haleon plc (NYSE:HLN - Free Report) by 567.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,563 shares of the company's stock after purchasing an additional 66,792 shares during the quarter. Scotia Capital Inc.'s holdings in Haleon were worth $750,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Sierra Ocean LLC acquired a new stake in shares of Haleon during the fourth quarter valued at about $26,000. Versant Capital Management Inc raised its position in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after purchasing an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Haleon during the 4th quarter valued at approximately $35,000. Toronto Dominion Bank grew its position in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after buying an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management bought a new stake in shares of Haleon in the fourth quarter worth $39,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Price Performance

Shares of NYSE HLN traded up $0.06 during midday trading on Friday, reaching $10.22. The company's stock had a trading volume of 16,644,855 shares, compared to its average volume of 7,148,029. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $46.16 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a one year low of $8.12 and a one year high of $10.80. The company has a 50 day moving average price of $10.09 and a 200 day moving average price of $9.80.

Haleon (NYSE:HLN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. On average, equities research analysts expect that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a report on Monday, March 3rd. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.